Immagina BioTechnology s.r.l.

Immagina BioTechnology s. r. l. is a biotechnology firm specializing in translatome technologies that enhance translational research, focusing on ribosomal dynamics and protein synthesis across various biological models.

Founded in 2014, Immagina BioTechnology s. r. l. is based in Trento, Italy, and provides advanced solutions for translational research.

The company was established by Massimiliano Clamer, who serves as CEO. Immagina has raised EUR 1 million in funding from investors including Hermann Hauser Investment and TBA Network, with the latest funding round occurring on February 1, 2020, bringing the total amount raised to EUR 1 million. Immagina BioTechnology specializes in advanced translatome products and services designed to facilitate translational research. Its core offerings, including RiboLace, LaceSeq, AHARIBO, and nano-tRNAseq, enhance the understanding of ribosomal dynamics and protein synthesis.

The company addresses challenges in disease mechanisms, drug discovery, and diagnostics related to neo-antigens and alternative proteoforms, primarily serving academic institutions, pharmaceutical companies, and biotech firms globally. In 2023, Immagina BioTechnology generated revenue of EUR 706,095. 9, with an EBITDA of EUR -973,307. 8.

The company primarily derives its revenue from direct sales of proprietary products and services targeting B2B transactions with research institutions and pharmaceutical companies. Immagina BioTechnology aims to expand its product offerings by developing new technologies tailored for translational research, expected to launch in the coming years. The company is also targeting expansion into North American and Asian markets by 2025. The recent funding of EUR 1 million will support these initiatives, enhancing their product development and market reach.